Sumitomo Mitsui Trust Group, Inc. 13D and 13G filings for CRISPR Therapeutics AG:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 06:08 am Sale | 2023-12-31 | 13G | CRISPR Therapeutics AG CRSP | Sumitomo Mitsui Trust Group, Inc. | 3,369,762 4.240% | -636,714 (-15.89%) | Filing |
| 2023-02-03 06:10 am Sale | 2022-12-31 | 13G | CRISPR Therapeutics AG CRSP | Sumitomo Mitsui Trust Group, Inc. | 4,006,476 5.110% | -312,995 (-7.25%) | Filing |
| 2022-02-04 06:05 am Purchase | 2021-12-31 | 13G | CRISPR Therapeutics AG CRSP | Sumitomo Mitsui Trust Group, Inc. | 4,319,471 5.640% | 482,648 (+12.58%) | Filing |
| 2021-02-05 06:10 am Purchase | 2020-12-31 | 13G | CRISPR Therapeutics AG CRSP | Sumitomo Mitsui Trust Group, Inc. | 3,836,823 5.390% | 786,938 (+25.80%) | Filing |